Breast Cancer
News
Racial disparities found in HER2-positive breast cancer care
Key clinical point: Trastuzumab is known to be beneficial in women with HER2-positive breast cancer, but black women were less likely to receive...
News
NCCN breast cancer RT guidelines: hypofractionation preferred
Key clinical point: NCCN guidelines on radiation therapy for locoregional treatment of breast cancer emphasize hypofractionated whole-breast...
Conference Coverage
NCCN fine-tunes breast cancer guidelines
News
Feds advance cancer moonshot with expert panel, outline of goals
Possible opportunities include vaccine development, early-detection technology, single-cell genomic analysis, immunotherapy, a focus on pediatric...
A Perfect Storm
A Perfect Storm: Interventions – Closing the survival gap
News
Adjuvant endocrine therapy for premenopausal breast cancer patients should be individualized
Key clinical point: Decisions about adjuvant endocrine therapies in premenopausal women with HR–positive, HER2-negative early breast cancer should...
Conference Coverage
Breast cancer treatment linked to mild systolic dysfunction
Breast cancer patients who underwent chemotherapy or radiotherapy had about a two-fold increased prevalence of mild systolic cardiac dysfunction a...
Conference Coverage
VIDEO: Trastuzumab plus lapatinib erases selected breast cancers
An unexpectedly dramatic benefit from combining trastuzumab and lapatinib when briefly treating women scheduled for breast cancer surgery has...
Conference Coverage
Inking bests suturing to mark breast tumor margins
Intraoperative suture placement is an inaccurate method for orienting breast tumor specimens for pathology.
Conference Coverage
10-year DCIS recurrence risk dwindles with age
Key clinical point: The risk of 10-year recurrence of ductal carcinoma in situ diminishes significantly with age. Major finding: The risk for...
Conference Coverage
Breast density pegged as risk factor for contralateral cancer
Extreme breast density on mammography in women with breast cancer is a strong independent risk factor for in situ or invasive cancer in the...